Lutikizumab

Summary

Lutikizumab (CHEMBL4594518) is a phase-3 clinical-stage antibody; indicated across 4 conditions including hidradenitis suppurativa and osteoarthritis, knee.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 4 conditions
• Clinical trials: 11

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4594518
Name	Lutikizumab
Type	Antibody
Max phase	3

Also known as: A-1234138, Abt-981, ABT-981, Lutikizumab, LUTIKIZUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hidradenitis suppurativa	3	MONDO:0006559	EFO:1000710
osteoarthritis, knee	2	MONDO:0005416	EFO:0004616
ulcerative colitis	2	MONDO:0005101	EFO:0000729
osteoarthritis	1	MONDO:0005178	MONDO:0005178

Clinical trials

Total trials: 11.

Phase distribution

Phase	Trials
PHASE2	9
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06468228	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT05139602	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy
NCT06257875	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06524635	PHASE2	RECRUITING	A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
NCT06548542	PHASE2	RECRUITING	Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn’s Disease
NCT06718101	PHASE2	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
NCT06865105	PHASE2	RECRUITING	Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis
NCT06972446	PHASE2	RECRUITING	A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
NCT02087904	PHASE2	COMPLETED	A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis
NCT02384538	PHASE2	COMPLETED	A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis
NCT01668511	PHASE1	COMPLETED	A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABT-981 in Patients With Osteoarthritis of the Knee

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).